# Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

> **NCT03856047** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 706 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** NNC0174-0833
- **DRUG:** Placebo (NNC0174-0833)
- **DRUG:** Liraglutide 3.0 mg
- **DRUG:** Placebo (Liraglutide 3.0 mg)

## Key facts

- **NCT ID:** NCT03856047
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2020-03-02
- **Final completion:** 2021-03-25
- **Target enrollment:** 706 (ACTUAL)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856047, "Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03856047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*